Last reviewed · How we verify
VH3810109
At a glance
| Generic name | VH3810109 |
|---|---|
| Sponsor | ViiV Healthcare |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
- Injection site erythema
- Upper respiratory tract infection
- Headache
- Injection site pain
- Injection site pruritus
- Muscle tightness
- Paraesthesia
- Post-traumatic pain
- Presyncope
- Viral infection
- Medical device site dermatitis
- Injection site bruising
Key clinical trials
- A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV (PHASE1)
- A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) (PHASE2)
- A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |